Key Points
-
A major impediment to the conduct of cost-effective and informative clinical trials of potential disease-modifying therapies for neurodegenerative disorders such as Alzheimer's disease (AD) is the absence of robust biomarkers for the early diagnosis of these disorders and for monitoring patient responses to new therapeutic interventions.
-
The complexity of neurodegenerative diseases, a number of which overlap, further adds to the challenge of identifying appropriate biomarkers.
-
Driven in part by drug discovery research, AD is at the forefront of biomarker development for neurodegenerative diseases, and many current concepts about ideal biomarkers for these disorders have come from AD research.
-
Ideal AD biomarkers should be: linked to fundamental features of AD neuropathology; validated in neuropathologically confirmed AD cases; able to detect AD early in its course and distinguish it from other dementias; reliable; non-invasive; simple to use; and inexpensive.
-
On the basis of extensive studies to date on potential AD biomarkers, it is highly likely that a combination of biomarkers will provide greater diagnostic accuracy than any single analyte.
-
A number of candidate AD biomarkers have emerged during the past decade Isoprostanes, tau, Aβ, sulphatides and homocysteine are among the most promising AD biomarker candidates, but there are also other potential AD biomarkers, such as Aβ precursor proteins, apolipoprotein E (APOE), 8-hydroxy-2′-deoxyguanosine, α1-antichymotrypsin, interleukin-6 (IL-6) and IL-6 receptor complex proteins, C-reactive protein, and C1q protein.
-
There is reason to be optimistic that a validated panel of AD biomarkers will be the outcome of the Alzheimer's Disease Neuroimaging Initiative and other research programmes. The successful accomplishment of this goal will enable the reliable diagnosis of AD in its early stages or even in its prodromal stages, as well as provide tests for reliably distinguishing AD from other forms of dementia.
Abstract
Rapid progress towards understanding the molecular underpinnings of neurodegenerative disorders such as Alzheimer's disease is revolutionizing drug discovery for these conditions. Furthermore, the development of models for these disorders is accelerating efforts to translate insights related to neurodegenerative mechanisms into disease-modifying therapies. However, there is an urgent need for biomarkers to diagnose neurodegenerative disorders early in their course, when therapy is likely to be most effective, and to monitor responses of patients to new therapies. As research related to this need is currently most advanced for Alzheimer's disease, this Review focuses on progress in the development and validation of biomarkers to improve the diagnosis and treatment of Alzheimer's disease and related disorders.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dobson, C. M. Protein folding and misfolding. Nature 426, 884–890 (2003).
Forman, M. S., Trojanowski, J. Q. & Lee, V. M.-Y. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nature Med. 10, 1055–1063 (2004).
Selkoe, D. J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nature Cell Biol. 6, 1054–1061 (2004). A review of protein misfolding and neurodegenerative disease.
Skovronsky, D. M., Lee, V. M.-Y. & Trojanowski, J. Q. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. Mech. Dis. 1, 151–170 (2006). A review of emerging therapies for AD, PD, FTD, and related disorders.
Cookson, M. R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 74, 29–52 (2005).
Dawson, T. M. & Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819–822 (2003).
Forman, M. S., Lee, V. M.-Y. & Trojanowski, J. Q. Nosology of Parkinson's disease: looking for the way out of a quackmire. Neuron 47, 479–482 (2005).
Greenamyre, J. T. & Hastings, T. G. Parkinson's — divergent causes, convergent mechanisms. Science 304, 1120–1122 (2004).
Savitt, J. M., Dawson, V. L. & Dawson, T. M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116, 1744–1754 (2006). A review of the diagnosis and treatment of PD.
Forman, M. S. et al. Frontotemporal dementia: clinicopathological correlations. Ann. Neurol. 59, 952–962 (2006).
McKeith, I. G. et al. Dementia with Lewy bodies: diagnosis and management: third report of the DLB Consortium. Neurology 65, 1863–1872 (2005). Updated criteria for the diagnosis of dementia with Lewy bodies and Parkinson's disease with dementia.
Cairns, N. J., Lee, V. M.-Y. & Trojanowski, J. Q. The cytoskeleton in neurodegenerative diseases. J. Pathol. 204, 438–449 (2004).
Lee, V. M.-Y., Kenyon, T. K. & Trojanowski, J. Q. Transgenic animal models of tauopathies. Biochem. Biophys. Acta 1739, 251–259 (2005).
Fillit, H. M. & Refolo, L. M. Advancing drug discovery for Alzheimer's disease. Curr. Alzheimer Res. 2, 105–109 (2005).
Zhang, B. et al. Microtubule binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a murine neurodegenerative tauopathy model. Proc. Natl Acad. Sci. USA 102, 227–231 (2005).
Michaelis, M. L. et al. β-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. J. Pharmacol. Exp. Ther. 312, 659–668 (2005).
Rice, A. et al. Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood–brain barrier in vitro and in situ. J. Med. Chem. 48, 832–838 (2005).
Dickey, C. A. et al. Development of a high throughput drug screening assay for the detection of changes in tau levels: proof of concept with HSP90 inhibitors. Curr. Alzheimer Res. 2, 231–239 (2005).
Pickhardt, M. et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J. Biol. Chem. 280, 3628–3635 (2005).
Pickhardt, M. et al. Screening for inhibitors of tau polymerization. Curr. Alzheimer Res. 2, 219–226 (2005).
Noble, W. et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102, 6990–6995 (2005).
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y. & Klein, P. S. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 423, 435–439 (2003).
The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the Working Group on Biological Markers of Alzheimer's Disease. Neurobiol. Aging 19, 109–116 (1998). A consensus report of the initial AD biomarker working group.
Frank, R. A. et al. Biological markers for therapeutic trials in Alzheimer's disase — Proceedings of The Biological measures Working Group: NIA Initiative on Neuroimaging in Alzheimer's Disease. Neurobiol. Aging 24, 521–536 (2003). A consensus report of promising AD biomarkers for study in the ADNI.
Blennow, K., de Leon, M. J. & Zetterberg, H. Alzheimer's disease. Lancet 368, 387–403 (2006).
Blennow, K. & Hampel, H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2, 605–613 (2003).
Clark, C. M. et al. Biochemical biomarkers of late-life dementia. Alzheimers Dement. 2, 287–293 (2006). A study of AD biomarker panel for the early diagnosis of AD.
Hansson, O. et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228–234 (2006). A longitudinal study of CSF biomarkers for MCI and its progression to AD.
de Leon, M. J. et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging 27, 394–401 (2006). A longitudinal study of CSF biomarkers for MCI and its progression to AD.
Thal, L. J. et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20, 6–15 (2006). A review of biomarkers for AD clinical trials.
Mueller, S. G. et al. The Alzheimer's Disease Neuroimaging Initiative. Neuroimaging Clin. N. Am. 15, 869–877 (2005). An overview of ADNI.
Clarke R., Smith D., Jobst D. M. & Refsum H. Folate, vitamin B12, and serum homocysteine levels in confirmed Alzheimer Disease. Arch. Neurol. 55, 1449–1455 (1998).
Seshadri S. et al. Plasma homocysteine as a risk factor for dementia and Alzheimers Disease. N. Engl. J. Med. 346, 476–483 (2002).
Saunders A. M. et al. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467–1472 (1993).
Hsiung G-Y. R., Sadovnick A. D. & Feldman H. Apolipoprotein E e4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. Can. Med. Assoc. J. 171, 863–867 (2004).
Clark, C. M. et al. Cerebrospinal fluid tau and β-amyloid: How well do these biomarkers reflect autopsy-confirmed dementia diagnoses. Arch. Neurol. 60, 1696–1702 (2003). The largest AD biomarker study of patients with dementia who were followed to autopsy.
Ibach, B. et al. Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol. Aging 27, 1202–1211 (2006). A study of AD biomarkers in a routine clinical setting.
Grossman, M. et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann. Neurol. 57, 721–729 (2005). A study of AD biomarkers in FTD patients.
Neumann, M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133 (2006). Ubiquitin-positive, tau- and α-synuclein-negative inclusions are formed by TDP-43 and are the defining lesions in nearly 50% of FTD patients.
Baker, M. et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916–919 (2006). Mutations in PGRN are pathogenic for familial FTLD-U.
Cruts, M. et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920–924 (2006). Mutations in PGRN are pathogenic for familial FTLD-U.
Tokuda, T. et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162–166 (2006). A study of CSF α-synuclein as a biomarker of PD.
Fagan, A. M. et al. Cerebropspinal fluid tau/Aβ42 predicts cognitive decline in nondemented older adults. Arch. Neurol. 8 Jan 2007 (doi:10.1001/archneur.64.3.noc60123).
Castano, E. M., Roher, A. E., Esh, C. L., Kokjohn, T. A. & Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol. Res. 28, 155–163 (2006).
Hu, Y., Malone, J. P., Fagan, A. M., Townsend, R. R. & Holtzman, D. M. Comparative proteomic analysis of intra- and inter-individual variation in human cerebrospinal fluid. Mol. Cell. Proteomics 4, 2000–2009 (2005).
Zhang, J. et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis. 7, 125–133 (2005).
Bateman, R. J., Wen, G., Morris, J. C. & Holtzman, D. M. Fluctuations of CSF amyloid b levels: Implications for a diagnostic and therapeutic biomarker. Neurol. (in the press).
Xu, S. & Gaskin, F. Increased incidence of anti-β-amyloid autoantibodies secreted by Epstein–Barr virus transformed β cell lines from patients with Alzheimer's disease. Mech. Ageing Dev. 94, 213–222 (1997).
Du, Y. et al. Reduced CSF levels of amyloid-β peptide antibody in Alzheimer's disease. Neurology 57, 801–805 (2001).
Abraham, C. R., Selkoe D. J. & Potter, H. Immunochemical identification of serine protease inhibitor α-1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52, 487–501 (1988).
Lanzrein, A. S. et al. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: IL 1β, IL 6, IL 1 receptor antagonist, TNFα, the soluble TNF receptors I and II, and α1-antichymotrypsin. Alzheimer Dis. Assoc. Disord. 12, 215–227 (1998).
Licastro, F., Morini, M. C., Polazzi, E. & Davis, L. J., Increased serum α 1 antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response. J. Neuroimmunol. 57, 71–75 (1995).
Licastro, F. et al. Increased plasma levels of IL 1, IL 6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J. Neuroimmunol. 103, 97–102 (2000).
Pirttila, T., Mehta, P. D., Frey H. & Wisniewski, H. M., α1 antichymotrypsin, and IL 1β are not increased in CSF or serum in Alzheimer's disease. Neurobiol. Aging 15, 313–317 (1994).
Henriksson, T. et al. Analysis and quantitation of the β-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay. J. Neurochem. 56, 1037–1042 (1991).
Palmert, M. R. et al. Soluble derivatives of the β amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease. Neurology 40, 1028–1034 (1990).
Sennvik, K. et al. Levels of α- and β-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 278, 169–172 (2000).
Van Nostrand, W. E. et al. Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc. Natl Acad. Sci. USA 89, 2551–2555 (1992).
Baskin, F., Rosenberg, R. N., Iyer, L., Hynan L. & Cullum, C. M. Platelet APP isoform ratios correlate with declining cognition in AD. Neurology 54, 1907–1909 (2000).
Di Luca, M. et al. Differential level of platelet amyloid β precursor protein isoforms: an early marker for Alzheimer disease. Arch. Neurol. 55, 1195–2000 (1998).
Padovani, A. et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch. Neurol. 59, 71–75 (2002).
Colciaghi, F. et al. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 62, 498–501 (2004).
Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383–421 (2000).
Webster, S. et al. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging 18, 415–421 (1997).
Schmidt, R. et al. Early inflammation and dementia: a 25 year follow-up of the Honolulu–Asia aging study. Ann. Neurol. 52, 168–174 (2002).
Licastro, F. et al. α-1-antichymotrypsin and oxidative stress in the peripheral blood from patients with probable Alzheimer disease: a short-term longitudinal study. Alzheimer Dis. Assoc. Disord. 15, 51–55 (2001).
Webster, S. & Rogers, J. Relative efficacies of amyloid β peptide (Aβ) binding proteins in Aβ aggregation. J. Neurosci. Res. 46, 58–66 (1996).
Smyth, M. D. et al. Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiol. Aging 15, 609–614 (1994).
Gabbita, S. P., Lovell M. A. & Markesbery, W. R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem. 71, 2034–2040 (1998).
Lovell M. A. & Markesbery, W. R. Ratio of 8 hydroxyguanine in intact DNA to free 8 hydroxyguanine is increased in the Alzheimer disease ventricular cerebrospinal fluid. Arch. Neurol. 58, 392–396 (2001).
Tumani, H., Shen, G., Peter J. B. & Bruck, W. Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer disease? Arch. Neurol. 56, 1241–1246 (1999).
Takahashi, M., Stanton, E., Moreno J. I. & Jackowski, G. Immunoassay for serum glutamine synthetase in serum: development, reference values, and preliminary study in dementias. Clin. Chem. 48, 375–378 (2002).
Wallin, A., Blennow K. & Rosengren, L. E. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. Dementia 7, 267–272 (1996).
Mecocci, P. et al. Serum anti-GFAP and anti S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia. J. Neuroimmunol. 57, 165–170 (1995).
Tanaka, J. et al. Enzyme-linked immunosorbent assay for human autobody to glial fibrillary acidic protein: higher titer of the antibody is detected in serum of patients with Alzheimer's disease. Acta Neurol. Scand. 80, 554–560 (1989).
Terryberry, J. W., Thor G. & Peter, J. B. Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis. Neurobiol. Aging 19, 205–216 (1998).
Hampel, H. et al. Discriminant power of combined cerebrospinal fluid tau protein and soluble gp130 in the diagnosis of Alzheimer's disease. Brain Res. 823, 104–112 (1999).
Diamandis, E. P., Yousef, G. M., Petraki C. & Soosaipillai, A. R. Human kallikrein 6 as a biomarker of Alzheimer's disease. Clin. Biochem. 33, 663–667 (2000).
Zighetti, M. L., Chantarangkul, V., Tripodi, A., Mannucci P. M. & Cattaneo, M. Determination of total homocysteine in plasma: comparison of the Abbott IMx immunoassay with high performance liquid chromatography. Haematologica 87, 89–94 (2002).
Kennard, M. L., Feldman, H., Yamada T. & Jefferies, W. A., Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nature Med. 2, 1230–1235 (1996).
Feldman, H. et al. Serum p97 levels as an aid to identifying Alzheimer's disease. J. Alzheimer Dis. 3, 507–516 (2001).
Kim, D. K. et al. Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease. Neuropsychopharmacology 25, 84–90 (2001).
Sjogren, M. et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J. Neurosci. Res. 66, 510–516 (2001).
Sjogren, M. et al. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 54, 1960–1964 (2000).
Hu, Y. Y. et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci. Lett. 320, 156–160 (2002).
Tohgi, H. et al. Alterations of 3 nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci. Lett. 269, 53–54 (1999).
Hensley, K. et al. Electrochemical analysis of protein nitrotyrosine and dityrosien in the Alzheimer brain indicates region-specific accumulation. J. Neurosci. 18, 8126–8132 (1998).
Hartmann, T. Cholesterol, A-β and Alzheimer's disease. Trends Neurosci. 24 (Suppl. 11), S45–S48 (2001).
Holtzman, D. M., Fagan A. M. & Han, X. CSF sulfatide levels: a possible biomarker for Alzheimer's disease at the earliest clinical stages. Neurology 58 (Suppl. 3), A361 (2002).
Han, X., Holtzman, D. M., McKeel, D. W., Kelly J. & Morris, J. C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 82, 809–818 (2002).
Masliah, E. The role of synaptic proteins in Alzheimer's disease. Ann. NY Acad. Sci. 924, 68–75 (2000).
Giasson, B. I., Lee, V. M-Y., Ischiropoulos H. & Trojanowski, J. Q. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's disease. Free Radic. Biol. Med. 32, 1264–1275 (2002).
Sheng, J. G. et al. Human brain S100 β and S100 β mRNA expression increases with age: pathogenic implications for Alzheimer's disease. Neurobiol. Aging 17, 359–363 (1996).
Acknowledgements
We thank M. Leonard for expert graphics and our colleagues for their contributions to the work summarized here, which has been supported by grants from the US National Institutes of Health, and the Marian S. Ware Alzheimer Program. Last, we are indebted to our patients and their families whose commitment to research has made our work possible.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (table)
Diagnostic performance of laboratory tests for AD (PDF 143 kb)
Related links
Related links
DATABASES
Entrez Gene
OMIM
FURTHER INFORMATION
Glossary
- Biomarker
-
A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention.
- Sensitivity
-
In this case, a sensitivity of 100% indicates that a diagnostic test identifies all patients with AD.
- Specificity
-
In this case, a test with 100% specificity identifies all individuals free of AD.
- Prior probability
-
The background prevalence of the disease in the population tested.
- Positive predictive value
-
The positive predictive value of an AD biomarker refers to the percentage of people who are positive for the biomarker and have definite AD at autopsy. A positive predictive value of 100% indicates that all patients with a positive test have the disease.
- Negative predictive value
-
The percentage of people with a negative test who, at autopsy, prove not to have the disease. A negative predictive value of 100% indicates that the test completely rules out the possibility that the individual has the disease when the test is performed.
- ELISA
-
Enzyme-linked immunosorbant assay. An immunochemical technique using antibodies to detect and quantify the presence of an antigen in a sample.
- APOE4
-
Apolipoprotein E4 allele. The susceptibility gene variant that is the most robust genetic risk factor for common, late-onset AD.
- Autosomal dominant
-
In this context, autosomal dominant refers to mutations (that is, changes in a gene) that are sufficient to cause disease when a single copy of the gene is affected by the mutation, and it is inherited by an individual who will develop the disease if he/she lives to the age of onset of the disease.
Rights and permissions
About this article
Cite this article
Shaw, L., Korecka, M., Clark, C. et al. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 6, 295–303 (2007). https://doi.org/10.1038/nrd2176
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd2176
This article is cited by
-
Chronic neuroinflammation during aging leads to cholinergic neurodegeneration in the mouse medial septum
Journal of Neuroinflammation (2023)
-
Neuro-nanotechnology: diagnostic and therapeutic nano-based strategies in applied neuroscience
BioMedical Engineering OnLine (2023)
-
Recent Advances in Photoelectrochemical Sensing of Alzheimer’s Biomarkers
BioChip Journal (2023)
-
Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice
Journal of Neural Transmission (2022)
-
Changes in the Brain Extracellular Matrix Composition in schizophrenia: A Pathophysiological Dysregulation and a Potential Therapeutic Target
Cellular and Molecular Neurobiology (2022)